Research Article
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
Table 3
Stability of ruxolitinib phosphate 2 mg/mL oral solution stored at 22–25°C and 2–8°C for 60 days.
| Storage | % ruxolitinib concentration remaining (mean ± SD) (n = 3) | Initial concentration (mg/mL) Day 0 | Day 5 | Day 15 | Day 21 | Day 28 | Day 36 | Day 42 | Day 60 |
| 22–25°C | 2.08 ± 0.01 | 100.2 ± 0.6 | 100.9 ± 1.8 | 100.6 ± 1.1 | 100.8 ± 0.5 | 99.5 ± 0.8 | 97.8 ± 1.5 | 96.6 ± 0.5 | 2–8°C | 2.07 ± 0.02 | 100.9 ± 1.9 | 101.8 ± 1.5 | 101.2 ± 1.2 | 99.2 ± 1.4 | 99.1 ± 1.8 | 100.6 ± 1.1 | 99.4 ± 0.6 |
| Storage | pH value (mean ± SD) (n = 3) | Day 0 | Day 5 | Day 15 | Day 21 | Day 28 | Day 36 | Day 42 | Day 60 |
| 22–25°C | 4.49 ± 0.01 | 4.45 ± 0.02 | 4.44 ± 0.01 | 4.44 ± 0.01 | 4.40 ± 0.01 | 4.40 ± 0.02 | 4.39 ± 0.01 | 4.36 ± 0.01 | 2–8°C | 4.48 ± 0.01 | 4.47 ± 0.01 | 4.47 ± 0.01 | 4.44 ± 0.02 | 4.43 ± 0.01 | 4.42 ± 0.02 | 4.39 ± 0.01 | 4.36 ± 0.01 |
|
|
|